Acute congestion is common in patients with heart failure (HF) and is associated with impaired renal function, reduced quality of life, hospital readmissions, and mortality. Current guidelines recommend optimal decongestion using diuretic therapy, mainly loop diuretics. Although acetazolamide has recently demonstrated efficacy in hospitalized patients, its role in ambulatory patients managed through remote telemonitoring remains to be established. This study aims to evaluate the efficacy of oral acetazolamide added to conventional treatment for decongesting ambulatory HF patients during congestive decompensations.
ACHIEVE is a Phase III multicenter, prospective, interventional, randomized, controlled, open-label superiority trial evaluating the efficacy of oral acetazolamide added to conventional treatment for decongestion in ambulatory patients with heart failure during congestive decompensation monitored by remote telemonitoring.
The primary objective is to assess, at Day 5, whether acetazolamide added to conventional treatment improves decongestion compared with standard treatment alone. Secondary objectives include evaluating efficacy, safety, and health economic outcomes, including quality of life, dyspnea, biological markers, unplanned consultations, hospitalizations, mortality, and hospital medical costs.

Start Date01 Oct 2026

Sponsor / Collaborator

University Hospital of Montpellier

NCT07593612

/ Not yet recruitingPhase 4

TACTIC-HF: Thiazide or Acetazolamide Combination Versus Intravenous Furosemide in Ambulatory Worsening Heart Failure - a Randomized Crossover Trial

TACTIC-HF is a prospective randomized crossover trial designed to compare three ambulatory diuretic strategies in patients with worsening heart failure treated in a specialized heart failure day-hospital program.
Participants will receive sequential treatment with:
1. intravenous furosemide alone,
2. intravenous furosemide combined with oral acetazolamide, and
3. intravenous furosemide combined with oral hydrochlorothiazide.
The primary objective is to compare short-term natriuretic response between strategies. Secondary objectives include assessment of urine output, congestion parameters, and renal/electrolyte safety.
Each participant will undergo repeated outpatient treatment sessions separated by washout periods, with standardized clinical and laboratory monitoring performed during each visit.
The study aims to evaluate pragmatic and clinically applicable ambulatory decongestion strategies using approved therapies commonly available in real-world practice.

Start Date15 Jun 2026

Sponsor / Collaborator

Instituto Cardiovascular De Buenos Aires SA

CTR20261197

/ Active, not recruitingNot Applicable

乙酰唑胺片在中国健康试验参与者中进行的单中心、随机、开放、单次（空腹/餐后）口服给药、两制剂、两序列、两周期、交叉的人体生物等效性预试验

[Translation] A single-center, randomized, open-label, single-dose (fasting/postprandial) oral administration, two-formulation, two-sequence, two-period, crossover human bioequivalence trial of acetazolamide tablets in healthy participants in China.

主要目的:观察中国健康试验参与者在空腹/餐后状态下单次口服受试制剂乙酰唑胺片(规格:0.25g;持证商和生产企业:石家庄格瑞药业有限公司)和参比制剂乙酰唑胺片(商品名:Diamox;规格:0.25g;持证商和生产企业:Sanwa Kagaku Kenkyusho Co.,Ltd.)后的药代动力学特征,初步评价空腹/餐后状态下两种制剂的生物等效性,为正式试验提供依据。次要目的:观察受试制剂乙酰唑胺片和参比制剂乙酰唑胺片(Diamox)在中国健康试验参与者中的安全性。

[Translation]

Primary Objective: To observe the pharmacokinetic characteristics of the test formulation acetazolamide tablets (0.25g; manufacturer and licensee: Shijiazhuang Green Pharmaceutical Co., Ltd.) and the reference formulation acetazolamide tablets (trade name: Diamox; 0.25g; manufacturer and licensee: Sanwa Kagaku Kenkyusho Co., Ltd.) after a single oral dose in Chinese healthy participants under fasting/postprandial conditions, and to preliminarily evaluate the bioequivalence of the two formulations under fasting/postprandial conditions, providing a basis for formal trials. Secondary Objective: To observe the safety of the test formulation acetazolamide tablets and the reference formulation acetazolamide tablets (Diamox) in Chinese healthy participants.

Start Date13 Apr 2026

Sponsor / Collaborator

Shijiazhuang Green Pharmaceutical Co., Ltd.

100 Clinical Results associated with Acetazolamide

100 Translational Medicine associated with Acetazolamide

100 Patents (Medical) associated with Acetazolamide

8,958

Literatures (Medical) associated with Acetazolamide

01 Oct 2026·CLINICAL NEUROLOGY AND NEUROSURGERY

CO2 Rebreathing as effective technique to assess cerebrovascular reserve in a resource constrained environment

Article

Author: Vlok, A J ; Gretschel, A ; Ebrahim, M Z ; Lamprecht, M E

BACKGROUND:

The use of premixed gases or intravenous acetazolamide to induce cerebral vasodilatation is well established, but not readily available in Low- and Middle-Income Countries.

OBJECTIVES:

Evaluate a low-cost, closed-circuit inhaled CO₂ method to induce cerebral vasodilatation, and thus measuring cerebrovascular reserve using CT perfusion imaging.

METHOD:

A retrospective review of patients who have already undergone a cerebral vascular reserve test at Tygerberg Hospital as their routine investigation and treatment. Twelve regions of interest (ROIs) were identified in a standardised layout, designed to exclude watershed areas. Non-pathological regions were designated Region Type 1, and pathological regions were designated Region Type 0. An increase in cerebral blood flow (CBF) > 10% was accepted as intact autoregulation. Statistical analysis clustered data by patient and used robust standard errors.

RESULTS:

Nine patients were reviewed. One was excluded based on a technical error in contrast medium administration. Another was excluded as all 12 ROIs were diseased. Seven patients yielded 84 ROIs, 43 (51%) of which showed no clinical or radiological features of pathology and were thus included in the final analysis. Across all 'non-pathological' ROIs, 83.72% (95% CI: 41.5% - 99.3%; p = 0.0002) demonstrated a > 10% increase in CBF after CO₂ rebreathing. The mean percentage increase was 28.5% (95% CI: 12.3 - 45.0%) CONCLUSION: The CO₂ rebreathing technique described herein produces a physiologically normal cerebrovascular reserve response in non-pathological brain tissue, comparable to more traditional methods.

01 Sep 2026·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Structural optimization of anti-hypoxic candidates guided by FGF21 and GDF15 mRNA expression

Article

Author: Zhang, Jinyan ; Li, Yiran ; Ren, Xuhong ; Yan, Xu ; Shi, Le ; Liu, Hailong ; Chen, Yuan ; He, Xinhua ; Zhou, Tao ; Yang, Xingxing ; Xu, Cheng ; Gao, Jianqin ; Chen, Jia ; Yin, Lehua ; Wang, Miao

Therapeutics for acute mountain sickness (AMS) remain limited, with no new drugs introduced since acetazolamide over half a century ago. Recently, H0802, whose target protein was unknown, was an FGF21 and GDF15 mRNA Expression regulator with promising anti-hypoxic effects. Given that FGF21 and GDF15 have been identified as key factors in hypoxia-related metabolic reprogramming, this study proposes a drug-discovery approach based on the RNA-regulation phenotypes of FGF21 and GDF15 to explore the structure-activity relationship of H0802. We designed and synthesized 28 new compounds and tested them on primary liver cells using mRNA expression of FGF21 and GDF15 as indicators. YXX0237 and YXX0248 emerged as the most promising candidates. They significantly increased FGF21 and GDF15 levels both in vitro and in vivo, thereby enhancing mice's hypoxia tolerance in closed hypoxia experiments. Preliminary safety tests showed that YXX0237 and YXX0248 have favorable safety profiles, with low cytotoxicity within the effective dose range, and their LD₅₀ values in mice exceed 500 mg/kg. Pharmacokinetic studies revealed that YXX0237 has higher bioavailability than YXX0248, enters the bloodstream quickly, and maintains stable exposure. Overall, this research offers a new strategy for developing small molecules that enhance hypoxia tolerance by inducing the expression of FGF21 and GDF15. Structure-activity relationship analysis provides a foundation for further structural optimization of H0802 derivatives. YXX0237 could be a potential candidate for treating hypoxia-related diseases.

01 Sep 2026·CLINICAL NEUROLOGY AND NEUROSURGERY

Impaired cerebral autoregulation in patients with moyamoya disease and moyamoya syndrome: A prospective cross-sectional study

Article

Author: Rinaldo, Lorenzo ; Brown, Robert D ; Meyer, Fredric B ; Webb, Kevin L ; Prink, Jessica D ; Klaas, James P ; Lanzino, Giuseppe ; Mason, Charles E ; Nasr, Deena M ; Khan, Muhib

Moyamoya disease and syndrome (MMDS) are rare cerebrovascular etiologies defined by stenosis of the distal intracranial internal carotid artery and proximal branches, with secondary development of small-vessel collaterals. Current techniques to characterize MMDS severity generally provide measurements in resting conditions (degree of stenosis, vessel collateralization, and regional oxygen delivery). In addition, some measurements of cerebral perfusion are performed with induced hypercapnia or acetazolamide to assess chemoreactivity. Despite the battery of exams, current techniques do not provide information about cerebral autoregulation. This study aimed to investigate dysfunction of cerebral autoregulation among patients with MMDS. Metrics of cerebral autoregulation were determined by transfer function analysis (TFA) of Middle Cerebral Artery velocities obtained with transcranial doppler ultrasound. Fourteen adult patients with MMDS and fifteen healthy, age- and sex-matched controls were included. Metrics of TFA (gain, phase, and coherence) were obtained within three frequency ranges (very low frequency (0.02-0.07 Hz), low frequency (0.07-0.2 Hz), and high frequency (0.2-0.5 Hz), in alignment with recommendations from the International Cerebral Autoregulation Research Network. Compared to the control group, the MMDS group had a significantly lower, very low frequency phase (P = 0.005), low frequency phase (P < 0.001), and high frequency phase (P = 0.010). In addition, the MMDS group had a significantly lower, low frequency coherence (P = 0.033). Regression analyses demonstrated a significant association between Suzuki grade and low frequency gain (m=-0.283, R²=0.089, P = 0.045) and high frequency gain (m=-0.338, R²=0.115, P = 0.026). Among patients with MMDS, there was a significant association between breath-hold index and low frequency phase (m=11.78, R²=0.171, P = 0.045), low frequency coherence (m=0.08, R²=0.242, P = 0.015), and high frequency coherence (m=0.06, R²=0.380, P = 0.001). Overall, these findings highlight a notable impairment in cerebral autoregulation in MMDS that appears to be associated with disease severity. Further studies are needed to assess whether cerebral autoregulation predicts disease progression and outcomes after surgical revascularization in MMDS patients.

News (Medical) associated with Acetazolamide

10 Jun 2026

·ir.incannex.com

Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility

NEW YORK and MELBOURNE, Australia, June 10, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative combination therapies and psychedelic-assisted treatments, is pleased to announce that it has received A$6,039,162.43 under the Australian Government’s Research and Development Tax Incentive Program. The Company also expects to receive an additional approximately A$5.1 million in future R&D Tax Incentive proceeds to be received in 2026. Combined, these proceeds represent more than A$11.1 million in non-dilutive capital that further strengthens the Company's balance sheet and enhances financial flexibility as Incannex advances its clinical development programs and executes on shareholder-focused capital allocation initiatives. Highlights: Received A$6.0 million under the Australian Government's Research and Development Tax Incentive Program Additional approximately A$5.1 million expected to be received in future R&D Tax Incentive proceeds More than A$11 million in total non-dilutive capital expected to be received Further strengthens Company's already robust balance sheet Provides additional flexibility to support advancement of key clinical assets, including IHL-42X and PSX-001 Supports ongoing capital allocation initiatives, including the Company's active share repurchase program The Australian Government's Research and Development Tax Incentive Program is designed to encourage innovation and scientific advancement by providing eligible companies with a cash refund for qualifying research and development activities conducted in Australia. Importantly, the proceeds are non-dilutive in nature, allowing Incannex to recover a significant portion of eligible research and development expenditure without issuing additional shares or taking on debt. Joel Latham, President and Chief Executive Officer of Incannex Healthcare, commented: “The receipt of more than A$6 million in non-dilutive capital is another important milestone for Incannex and further strengthens what we believe is one of the strongest balance sheets among clinical-stage biotechnology companies of our size. “Importantly, these proceeds are being received without issuing a single additional share. At a time when many biotechnology companies are reliant on dilutive financings to fund development activities, Incannex continues to strengthen its balance sheet through disciplined capital management and strategic utilization of government innovation incentives. “Combined with our existing cash position and debt-free balance sheet, these proceeds provide additional flexibility as we continue advancing our key clinical programs, including the recently commenced DReAMzz study for IHL-42X, while also supporting shareholder-focused capital allocation initiatives such as our active share repurchase program. “We believe the market continues to significantly undervalue the strength of our balance sheet, the progress across our clinical programs and the multiple value creation opportunities ahead of us. The receipt of this additional non-dilutive capital further reinforces our ability to execute on our strategy while maintaining a strong financial foundation.” About Incannex Healthcare Inc. Incannex is leading the way in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnea, rheumatoid arthritis and generalized anxiety disorder. The Company is advancing three clinical-stage product candidates based on evidence-based innovation and supported by streamlined operations. Incannex’s lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnea. In a Phase 2 development program, IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. Approved for Phase 2 clinical development, PSX-001 is an oral synthetic psilocybin treatment for the treatment of generalized anxiety disorder. Incannex’s programs target disorders that have limited, inadequate, or no approved pharmaceutical treatment options. For additional information on Incannex, please visit our website at www.incannex.com. Forward-Looking Statements Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to management’s expectations regarding the development, regulatory progress and commercialization of the Company’s drug candidates, including IHL-42X, expectations regarding use of the Company’s cash on hand, the potential value of the Company’s drug candidates and business, including these values as compared to available cash, opportunities, the strategy, timing and future development of the Company’s drug candidates, the potential value of the Company and its drug candidates and potential shareholder value. When or if used in this communication, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to the Company, its operations or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management’s current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the risk that the Company’s estimates and current projections regarding the sufficiency of its current cash on hand to fund the Company’s planned operations may be incorrect and the Company may use these resources faster than anticipated, and other risks described in the section entitled “Risk Factors” described in the prospectus supplement and in the Company’s annual report on Form 10-K for the fiscal year ended June 30, 2025, filed with the SEC on September 29, 2025, and the other reports it files from time to time, including subsequently filed annual, quarterly and current reports, which can be obtained on the SEC website at www.sec.gov and are made available on the Company’s website upon their filing with the SEC. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law. Investor & Media Contacts CORE IR (212) 655-0924 investors@incannex.com media@incannex.com.au

Phase 2

04 Mar 2026

·www.prnewswire.com

First-in-Human Use of CereVasc® eShunt® System in Idiopathic Intracranial Hypertension Demonstrates Sustained Clinical Outcomes

Compassionate Use Case Reports Continued Symptom Improvement and Imaging-Confirmed Device Patency Through Three-Year Follow-Up BOSTON, March 4, 2026 /PRNewswire/ -- CereVasc, Inc., a clinical-stage medical device company developing novel minimally invasive treatments for neurological diseases, today announced the publication of a first-in-human case report describing the use of the eShunt System to treat medically refractory idiopathic intracranial hypertension (IIH), formerly known as pseudotumor cerebri. The case report, published in Stroke: Vascular and Interventional Neurology, details treatment with the eShunt System in a patient whose symptoms persisted despite medical therapy. Led by Pedro Lylyk, MD, and colleagues at ENERI Medical Institute in Buenos Aires, Argentina, the case involved a 50-year-old man with a history of chronic IIH whose symptoms had progressed despite treatment with acetazolamide and serial lumbar punctures. Following regulatory and ethics approval for compassionate use, the patient underwent minimally invasive endovascular treatment with the eShunt System. Case Summary: 35-day follow-up The patient reported improvement in headaches, diplopia, and overall quality of life Reduced cerebrospinal fluid (CSF) opening pressure compared to pre-treatment baseline opening pressure Magnetic resonance imaging (MRI) showed decreased optic nerve sheath distension compared to baseline MRI, and gadolinium-enhanced cisternography confirmed CSF flow through the implant into the internal jugular vein 5-month follow-up The patient reported persistent symptom improvement Ability to discontinue acetazolamide and nonsteroidal anti-inflammatory medications Imaging demonstrated maintained device patency 3-year follow-up MRI continued to demonstrate a patent eShunt Implant with sustained CSF drainage The patient reported sustained improvement of headaches and visual symptoms No device- or procedure-related complications, including over drainage, thrombosis, stroke, occlusion, displacement, or subdural collections were observed during follow-up "The eShunt System offers a novel, minimally invasive endovascular approach that successfully reduced intracranial pressure, alleviated optic nerve edema, and provided sustained symptomatic relief in this medically refractory IIH patient, with device patency maintained through three years of follow-up," said Pedro Lylyk, M.D., CEO of ENERI Medical Institute and Clinica la Sagrada Familia and lead author of the case report. Dan Levangie, Chairman and CEO of CereVasc, added: "This first-in-human experience of the eShunt System in idiopathic intracranial hypertension highlights the potential of our minimally invasive technology to expand treatment options for patients living with elevated intracranial pressure. By emulating natural CSF drainage pathways without open surgery, the eShunt System is designed to address limitations of current therapies and supports our ongoing commitment to advancing solutions that improve patient outcomes and quality of life." About Idiopathic Intracranial Hypertension Idiopathic Intracranial Hypertension (IIH) is characterized by elevated pressure around the brain without an identifiable structural cause. The condition is associated with chronic headaches, nausea, tinnitus, papilledema, visual disturbances, and risk of progressive vision loss. IIH affects approximately 1–2 individuals per 100,000 annually in the general population, with substantially higher incidence among women of childbearing age and individuals with obesity. Current treatment options include medication, repeat lumbar punctures, venous sinus stenting, or ventriculoperitoneal (VP) shunting, each with associated risks and limitations. About CereVasc, Inc. Located in Massachusetts' healthcare hub, CereVasc, Inc., is a clinical-stage medical device company focused on the development of novel, minimally invasive treatments for patients with neurological diseases. Its initial product, the eShunt System, employs an innovative percutaneous transvenous-transdural access to the central nervous system intended to enable the first minimally invasive treatment for communicating hydrocephalus (CH). The eShunt system concept originated from Tufts Medical Center physicians Carl Heilman, MD, Neurosurgeon and Chair Emeritus of Neurosurgery, and Adel Malek, MD, PhD, Chief of Neurovascular Surgery and Director of Cerebrovascular and Endovascular Neurosurgery. The patented eShunt System includes an endovascularly implantable cerebrospinal fluid shunt and delivery components, which are designed to treat CH without invasive surgery. For additional information, please visit our website at . The eShunt System is an investigational device and has not been approved by FDA or any other regulatory agency for commercial sale. Its safety and effectiveness have not yet been fully established. Company Contact: DJ Cass CereVasc, Inc. [email protected] Media Contacts: Ethan Metelenis Precision AQ [email protected] SOURCE CereVasc 21% more press release views with Request a Demo

Clinical ResultClinical Study

12 Dec 2025

·www.einpresswire.com

Rangsit University study shows simple bypass protocol improves outcomes in chronic cerebral occlusion

Single-barrel bypass guided by mean transit time improved symptoms in 80% of patients with chronic cerebral occlusion or moyamoya disease BEIJING, BEIJING, CHINA, December 12, 2025 / EINPresswire.com / -- Single-barrel bypass guided by mean transit time improved symptoms in 80% of patients with chronic cerebral occlusion or moyamoya disease Chronic cerebral arterial occlusion and moyamoya disease are significant causes of stroke, particularly in regions where advanced diagnostic tools are limited. This study from Rajavithi Hospital assessed a simple bypass protocol that uses mean transit time to identify candidates for single-barrel bypass surgery. Thirty patients were evaluated, and 80 percent showed postoperative improvement with high graft patency and minimal complications. The findings support mean transit time as an effective non-stress method for guiding surgical decision-making. Ischemic strokes represent a major health burden and are the leading cause of death in Thailand, with more than 250,000 new cases each year. Chronic cerebral arterial occlusion and moyamoya disease are important contributors to this problem and often require careful evaluation of cerebral blood flow. In many regions, advanced stress tests for cerebrovascular reserve assessment are unavailable, which makes simple and reliable alternatives important for patient care. A study from Rajavithi Hospital, College of Medicine, Rangsit University, led by Dr. Ittipon Gunnarut and Dr. Kritsada Buakate, evaluated whether a simple bypass protocol guided by mean transit time (MTT)—the average time taken by blood to travel through a specific part of the body—could reliably improve outcomes in patients with chronic cerebral arterial occlusion or moyamoya disease. The research, made available online on October 27, 2025 in Volume 11, Issue 27 of the Chinese Neurosurgical Journal . The research reviewed patients who underwent single-barrel bypass surgery between 2010 and 2024 and had complete preoperative perfusion imaging and postoperative follow-up records. MTT prolongation of more than six seconds was used as the indicator of hemodynamic compromise. A total of thirty patients were included in the study. Before surgery, 23.3 percent had MTT delay on both sides, and the average Modified Rankin Scale—a measure of the degree of disability after a stroke—score was 2.50. “Our results show that prolonged mean transit time is a practical indicator for selecting patients who can benefit from bypass surgery, especially in regions where stress tests are not available,” says Dr. Gunnarut. 80% of patients experienced symptom improvement with over 90% intraoperative graft patency (the ability of a blood vessel graft to remain open and allow unobstructed blood flow). Only one complication occurred—a brainstem infarction unrelated to the bypass site. The mean postoperative Modified Rankin Scale score improved to 2.0, indicating better functional outcomes. They presented two clinical examples. In the first case, a man with transient ischemic attacks and right eye blindness had right internal carotid artery occlusion with bilateral MTT prolongation. After a single-barrel superficial temporal artery to middle cerebral artery bypass, his symptoms improved, and postoperative imaging showed better perfusion. In the second case, a woman with left-side weakness experienced complete recovery of motor strength after surgery, and imaging also improved. The study highlights limitations of stress tests, such as acetazolamide or carbon dioxide challenges, which may provoke ischemic events and are unavailable in many countries. Non-stress MTT testing avoids these risks, making it suitable for resource-limited settings. These findings align with previous studies showing that MTT correlates with cerebrovascular reserve and can predict postoperative improvement. Dr. Buakate noted, “The simple bypass protocol provided good clinical outcomes with a very low complication rate and can be used in hospitals that do not have access to more complex testing.” These results support the usefulness of MTT in identifying candidates who may benefit from revascularization. The study acknowledges several limitations, including its retrospective design, potential missing postoperative imaging data, and the influence of comorbidities and variations in perioperative management. Despite these factors, the results demonstrate that the simple bypass protocol is effective for patients with chronic cerebral occlusion or moyamoya disease. It provides a practical yet cost-effective method for evaluating cerebrovascular reserve in settings where stress-based testing cannot be performed. Yi Lu Chinese Neurosurgical Journal 1059978478 ext. luyi617@sina.cn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Clinical ResultAHA

100 Deals associated with Acetazolamide

External Link

KEGG	Wiki	ATC	Drug Bank
D00218	Acetazolamide	S01EC01	DB00819

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pre-Eclampsia	Japan	Sanwa Kagaku Kenkyusho Co., Ltd.	02 Jun 1994
Sleep Apnea Syndromes	Japan	Sanwa Kagaku Kenkyusho Co., Ltd.	29 Mar 1988
Ocular Hypertension	China	Tianjin Lisheng Pharmaceutical Co., Ltd.	01 Jan 1983
Acidosis, Respiratory	Japan	Sanwa Kagaku Kenkyusho Co., Ltd.	29 Mar 1955
Glaucoma	Japan	Sanwa Kagaku Kenkyusho Co., Ltd.	29 Mar 1955
Meniere Disease	Japan	Sanwa Kagaku Kenkyusho Co., Ltd.	29 Mar 1955
Premenstrual Syndrome	Japan	Sanwa Kagaku Kenkyusho Co., Ltd.	29 Mar 1955
Endocrinology and Metabolic Disease	United States	Teva Women's Health, Inc.	25 Jun 1954
Acute angle-closure glaucoma	United States	Teva Branded Pharmaceutical Products R&D LLC	27 Jul 1953
Altitude Sickness	United States	Teva Branded Pharmaceutical Products R&D LLC	27 Jul 1953
Edema	United States	Teva Branded Pharmaceutical Products R&D LLC	27 Jul 1953
Epilepsy	United States	Teva Branded Pharmaceutical Products R&D LLC	27 Jul 1953
Glaucoma, Open-Angle	United States	Teva Branded Pharmaceutical Products R&D LLC	27 Jul 1953
Secondary glaucoma	United States	Teva Branded Pharmaceutical Products R&D LLC	27 Jul 1953

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Rheumatoid Arthritis	Preclinical	China	Anhui Medical University	12 May 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04975269 (DRAIN, Pubmed \| Lancet Neurol)	Phase 2	Hydrocephalus, Normal Pressure	50	Acetazolamide	zgaeqbzodi(fplywnoord) = bjcrceoqgf mqebzmnqbs (hykhrvsivk ) View more	Negative	01 Jun 2026
				Placebo	zgaeqbzodi(fplywnoord) = moahymbtau mqebzmnqbs (hykhrvsivk ) View more
AUA2026	Not Applicable	Weight Loss \| Migraine Disorders	246	Topiramate	migpaoqovn(pxpyxywvai) = mnupfdhglk maohgezvdg (yvbmhywjls, 4.27 - 5.65)	Positive	15 May 2026
				Zonisamide	migpaoqovn(pxpyxywvai) = khpshazfmv maohgezvdg (yvbmhywjls, 5.84 - 10.96)
NCT05589792 (Pubmed \| Thorax)	Phase 2	Sleep Apnea Syndromes	11	Acetazolamide 500 mg	divoivyqrt(xblbdvgkqk) = ohtydcikcy jmybwvkbmc (tpviakauqo ) View more	Positive	04 Mar 2026
				Placebo	divoivyqrt(xblbdvgkqk) = lxusfooxgv jmybwvkbmc (tpviakauqo ) View more
NCT03156231 (Pubmed \| J Clin Sleep Med)	Phase 2	Pulmonary Disease, Chronic Obstructive	43	Acetazolamide 375 mg/day	gbghzszspx(vhkewqldyy) = hvjxajigqg pybkeruivs (ibwpsshkfx ) View more	Positive	01 Dec 2025
				Placebo	yxispfgxga(oiazdqhiox) = dnfnjpwnga syyizcxayx (bznxdkojuw ) View more
NCT03540914 (Pubmed \| J Am Heart Assoc)	Phase 2	Heart Failure	171	Acetazolamide 375 mg/day	kkckhxbnld(nvtlbahxmv) = pxgcopmnmt murpgewomo (fvrpdmifno ) View more	Negative	02 Sep 2025
				Placebo	kkckhxbnld(nvtlbahxmv) = hasinpxyti murpgewomo (fvrpdmifno )
NCT05411991 (DECONGEST, CTgov)	Phase 4	Volume overload \| Heart Failure \| Drug-Related Side Effects and Adverse Reactions	107	UNa measurement after intravenous loop diuretic bolus+Intravenous bumetanide TID+Intravenous canrenoate 200 mg OD+Intravenous acetazolamide 500 mg OD+chlorthalidone (Intervention Arm)	qapdmesjun = tlxblvzdnw cafblpcjcq (dzamkbwqus, slibxqfbes - hgfgkdmhkr) View more	-	08 Aug 2025
				Usual AHF care (Control Arm)	qapdmesjun = paflpmpcvv cafblpcjcq (dzamkbwqus, koyugxpnuo - fjkgcsnqaz) View more
NCT04679389 (CTgov)	Phase 2/3	Congenital Disorder of Glycosylation Type 1A \| Ataxia	25	Acetazolamide (Acetazolamide)	cptlvrygmb(dtfryfmqww) = xpsfmwpmvl ukacmpqmuf (fxapweerpm, 3.20) View more	-	20 Mar 2025
				Placebo (Placebo)	cptlvrygmb(dtfryfmqww) = usavfdaqyb ukacmpqmuf (fxapweerpm, 3.23) View more
NCT04639193 (RESCUE-Combo, Pubmed \| Ann Am Thorac Soc)	Phase 2	Sleep Apnea, Obstructive	20	Acetazolamide+eszopiclone	uoxwtlupyl(gfnfjgtxmh) = qofudvtupu rvvizzewwj (bgiwydszba, -24.1 to -5.2)	Positive	08 Nov 2024
NCT03505788 (ADVOR Trial \| Advor, CTgov)	Phase 4	Volume overload \| Metabolic Diseases \| Acute decompensated heart failure	519	placebo (Placebo)	yqrckwdbqn = nmwmvnbaki uzgfkaindt (mnbbtwrlvo, vcpndkrgkw - vdrpxcwtcu) View more	-	28 Oct 2024
				Acetazolamide (Acetazolamide)	yqrckwdbqn = qdpshpwpau uzgfkaindt (mnbbtwrlvo, gcvwjbkfjh - cxhskzphft) View more
NCT05473364 (Acetazolamide in Persons with Type 1 Diabetes, Pubmed \| J Am Soc Nephrol)	Phase 1	Diabetes Mellitus, Type 1	12	Acetazolamide 62.5 mg	blvsxxksmg(oqmadlvwcd) = ryovvmwqkt dzuuzfjhqa (fhbbacdhug ) View more	Positive	08 Oct 2024
				Acetazolamide 125 mg	blvsxxksmg(oqmadlvwcd) = dbynbwliyg dzuuzfjhqa (fhbbacdhug ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis